



NeonMind Biosciences Inc.

Symbol: CSE: NEON | **OTCQB:** NMDBF

Market Cap: 16.9M

Sector: Psychedelics

Purpose: Raise Awareness / Open Market Buying

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.

Investor Bullet Points:

- NeonMind Biosciences (Canada: NEON) (U.S.: NMDBF) (Europe: 6UF) is a biotechnology company focused on utilizing psychedelics as a treatment for chronic weight management in obese patients
- In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5-HT_{2A}, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate employs low-dose psilocybin as an agonist to the 5-HT_{2C} receptor, which controls appetite.
- NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

Rob Tessarolo, President & CEO

Over 25 years of experience in the pharmaceutical industry, and an impressive track record of scaling high growth organizations in the industry through product innovation and M&A. He has successfully navigated drug development and the regulatory process in Canada and the U.S. His commercial and business development experience extends across numerous therapeutic areas and includes obesity, addiction, and neurologic disorders. His experience spans over two decades at companies including Mind Medicine, Cipher Pharmaceuticals, Celgene Corporation, Watson Pharmaceuticals, Actavis Pharmaceuticals and Biovail Pharmaceuticals. He has led organizations in Canada and the US market. Robert brings extensive enterprise leadership experience including internal and external stakeholder responsibilities, capital market roadshows throughout North America, capital and investor relations strategy, quarterly public company reporting, RTO transactions and go-public listing process. He has completed numerous pharmaceutical deal transactions involving asset licensing, R&D